仁和药业
(000650)
| 流通市值：80.15亿 | | | 总市值：84.28亿 |
| 流通股本：13.31亿 | | | 总股本：14.00亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,833,451,760.31 | 1,975,091,476.41 | 985,645,075.41 | 4,074,892,927.7 |
| 营业收入 | 2,833,451,760.31 | 1,975,091,476.41 | 985,645,075.41 | 4,074,892,927.7 |
| 二、营业总成本 | 2,337,881,030.25 | 1,609,099,953.45 | 816,617,127.68 | 3,362,231,766.1 |
| 营业成本 | 1,801,340,191.69 | 1,252,352,860.52 | 622,445,576.16 | 2,528,880,748.84 |
| 税金及附加 | 26,633,548.97 | 17,844,210.23 | 7,613,839.94 | 46,481,323.46 |
| 销售费用 | 263,387,663.72 | 166,908,795.8 | 93,047,616.52 | 462,529,141.32 |
| 管理费用 | 219,380,428.96 | 151,194,942.43 | 86,323,164.56 | 290,804,042.59 |
| 研发费用 | 26,403,032.09 | 20,629,325.54 | 8,129,206.47 | 43,848,791.76 |
| 财务费用 | 736,164.82 | 169,818.93 | -942,275.97 | -10,312,281.87 |
| 其中:利息费用 | 63,140.93 | 43,293.13 | 22,159.93 | 166,965.55 |
| 其中:利息收入 | 2,073,900.85 | 1,077,983.98 | 1,208,614.71 | 13,630,489.15 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -827,369 | 39,303.94 | -16,689.62 | 16,033,837.69 |
| 加:投资收益 | 38,329,882.06 | 26,729,093.05 | 14,745,068.49 | 72,701,938.99 |
| 资产处置收益 | 2,050,698.58 | 2,000,511.4 | 511.4 | 1,365,132.54 |
| 资产减值损失(新) | 107,491.34 | 99,651.05 | 54,557.6 | -113,319,610.32 |
| 信用减值损失(新) | -8,656,206.79 | -8,655,966.25 | 60,000 | -28,610,551.19 |
| 其他收益 | 90,406,775.28 | 75,432,870.35 | 64,973,191.97 | 114,153,767.07 |
| 四、营业利润 | 616,982,001.53 | 461,636,986.5 | 248,844,587.57 | 774,985,676.38 |
| 加:营业外收入 | 1,978,432.93 | 890,587.95 | 633,016.94 | 4,975,515.52 |
| 减:营业外支出 | 2,908,090.51 | 1,377,214.67 | 1,100,399.31 | 5,342,959.96 |
| 五、利润总额 | 616,052,343.95 | 461,150,359.78 | 248,377,205.2 | 774,618,231.94 |
| 减:所得税费用 | 146,942,194.74 | 105,909,502.89 | 51,641,559.79 | 208,032,518.93 |
| 六、净利润 | 469,110,149.21 | 355,240,856.89 | 196,735,645.41 | 566,585,713.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 469,110,149.21 | 355,240,856.89 | 196,735,645.41 | 566,585,713.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 379,135,177.06 | 290,426,249.89 | 164,307,562.31 | 481,911,678.36 |
| 少数股东损益 | 89,974,972.15 | 64,814,607 | 32,428,083.1 | 84,674,034.65 |
| 扣除非经常损益后的净利润 | 276,937,850.51 | 206,790,410.23 | 101,976,280.99 | 334,646,562.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.21 | 0.12 | 0.35 |
| (二)稀释每股收益 | 0.27 | 0.21 | 0.12 | 0.35 |
| 九、综合收益总额 | 469,110,149.21 | 355,240,856.89 | 196,735,645.41 | 566,585,713.01 |
| 归属于母公司股东的综合收益总额 | 379,135,177.06 | 290,426,249.89 | 164,307,562.31 | 481,911,678.36 |
| 归属于少数股东的综合收益总额 | 89,974,972.15 | 64,814,607 | 32,428,083.1 | 84,674,034.65 |
| 公告日期 | 2025-10-31 | 2025-08-26 | 2025-04-29 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |